SC
NYMX

Scotia Capital’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Scotia Capital’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-18,195
Closed -$79K – 624
2014
Q3 		$79K Sell
18,195
-400
-2% -$1.96K ﹤0.01% 571
2014
Q2 		$92K Buy
18,595
+202
+1% +$1.04K ﹤0.01% 554
2014
Q1 		$100K Buy
+18,393
New +$107K ﹤0.01% 554

Other funds holding NYMX

AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
WP
WMS Partners Towson, Maryland $1.78B AUM 11.82% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
MCM
Marathon Capital Management Hunt Valley, Maryland $494M AUM 42.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BAS
Brown Advisory Securities Baltimore, Maryland $27.3M AUM 10.67% 1-Year Est. Return
GG
Gofen & Glossberg Chicago, Illinois $3.89B AUM 11.97% 1-Year Est. Return

Scotia Capital's NYMX Position: Q4 2014 in Review

Scotia Capital sold out of Nymox Pharmaceutical Corp (NYMX) in Q4 2014, closing a stake of 18,195 shares — an estimated $79K sold.

Scotia Capital first reported a position in NYMX in Q1 2014 and held it in 3 quarters. The position peaked at $100K in Q1 2014. 25 funds tracked by Wall St. Rank hold NYMX as of Q4 2014.

  • Scotia Capital reported no remaining Nymox Pharmaceutical Corp position as of Q4 2014 after selling out during the quarter.
  • Scotia Capital sold 18,195 Nymox Pharmaceutical Corp shares in Q4 2014, an estimated $79K.
  • Scotia Capital first reported a position in Nymox Pharmaceutical Corp in Q1 2014 and held it in 3 quarters.
  • Scotia Capital's Nymox Pharmaceutical Corp position peaked at $100K in Q1 2014.
  • 25 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q4 2014.

Based on Scotia Capital's 13F filing for Q4 2014, filed 13 Feb 2015.